Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. - Wikidata - awgldk - TriplyDB

Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis.

Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis.

http://www.wikidata.org/entity/Q36494558

about

The innate immune system in demyelinating disease Imaging Axonal Degeneration and Repair in Preclinical Animal Models of Multiple Sclerosis Nanotechnology in neurology: Genesis, current status, and future prospects The Non-Obese Diabetic Mouse Strain as a Model to Study CD8(+) T Cell Function in Relapsing and Progressive Multiple Sclerosis Potential Suppressive Effects of Two C60 Fullerene Derivatives on Acquired Immunity Fullerene-biomolecule conjugates and their biomedicinal applications.Myelin basic protein induces inflammatory mediators from primary human endothelial cells and blood-brain barrier disruption: implications for the pathogenesis of multiple sclerosis Transcriptional alteration of matrix-related gene expression in cultured human disc cells by nanoparticles of a bismethanophosphonate fullerene.Neuroprotective and anti-inflammatory effects of estrogen receptor ligand treatment in mice.A beta-lactam antibiotic dampens excitotoxic inflammatory CNS damage in a mouse model of multiple sclerosis.CD200R1 agonist attenuates mechanisms of chronic disease in a murine model of multiple sclerosis.Evaluation of the fullerene compound DF-1 as a radiation protector.In vivo evidence of glutamate toxicity in multiple sclerosis.Review: Mitochondria and disease progression in multiple sclerosis Pathomechanisms underlying X-adrenoleukodystrophy: a three-hit hypothesis.Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation.Application of fullerenes in nanomedicine: an update.Xanthine oxidase mediates axonal and myelin loss in a murine model of multiple sclerosis Deletion of mitochondrial anchoring protects dysmyelinating shiverer: implications for progressive MS.Blocking GluR2-GAPDH ameliorates experimental autoimmune encephalomyelitis Astrocyte response to IFN-γ limits IL-6-mediated microglia activation and progressive autoimmune encephalomyelitis.The serine protease inhibitor SerpinA3N attenuates neuropathic pain by inhibiting T cell-derived leukocyte elastase.Effect of intra-membrane C60 fullerenes on the modulus of elasticity and the mechanical resistance of gel and fluid lipid bilayers.Time-Dependent Progression of Demyelination and Axonal Pathology in MP4-Induced Experimental Autoimmune Encephalomyelitis.Platelets contribute to the pathogenesis of experimental autoimmune encephalomyelitis.Disruption of NMDA receptors in oligodendroglial lineage cells does not alter their susceptibility to experimental autoimmune encephalomyelitis or their normal development.The CCL2 synthesis inhibitor bindarit targets cells of the neurovascular unit, and suppresses experimental autoimmune encephalomyelitis.Abnormal NMDA receptor function exacerbates experimental autoimmune encephalomyelitis Neuropathic pain in animal models of nervous system autoimmune diseases.Lipids and lipid-reactive antibodies as biomarkers for multiple sclerosis.IL-10-dependent Tr1 cells attenuate astrocyte activation and ameliorate chronic central nervous system inflammation Modeling the heterogeneity of multiple sclerosis in animals Nanomedicine in cerebral palsy.Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE.MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies.Demyelinated axons and motor function are protected by genetic deletion of perforin in a mouse model of multiple sclerosis.Neuromuscular electrical stimulation and dietary interventions to reduce oxidative stress in a secondary progressive multiple sclerosis patient leads to marked gains in function: a case report.Neurodegenerative disorders and nanoformulated drug development.Absence of system xc- on immune cells invading the central nervous system alleviates experimental autoimmune encephalitis.Multiple sclerosis: experimental models and reality.

P2860

Q24597958-D5AD7240-67D5-44F1-9389-64BD7239A4B0 Q26744629-872D17D0-3BB6-4E03-BCAD-A79A86013184 Q26771772-BEBA4DB2-09DC-4B70-967E-AB4F63246B49 Q26777944-C154CC77-60E6-41D9-943A-AD490841D515 Q28390965-719F11C4-316F-4079-986C-9E43675A4E03 Q28393292-5AFB0C5F-AED7-45BC-9A33-484D637AE270 Q28910423-0FB6175F-DFC3-44A7-BF89-BBCAC0F6A595 Q30450761-E1DBB22A-A874-4A48-A491-7735013232EF Q30478676-D5470E86-1E3E-4F74-9CF7-B6452175BF82 Q33367112-95871AD1-E94D-438E-AA8E-10AB01F7AF89 Q33725044-DA6FD9CE-5022-4A82-98D6-5ECC9BA0BD61 Q33881319-122E1E8A-CBB5-4466-8BAC-7E2A6AB3D356 Q34081836-F11AB76F-EA77-4139-9D56-5966C86ECB4A Q34308687-1F5569F8-BC0D-4496-BE1E-8BC9A12099DF Q34491978-BE9D7FA9-0A6B-43E5-B05A-181FC31A102C Q34632490-E48043D3-19A3-422E-B020-7128D435F25B Q34803596-03A68C7F-1610-4B04-9115-CF24EF6B2D8A Q34949303-65D8D4D3-E584-4463-8E04-6807D348ACDC Q35236885-4C6C154A-76CE-488F-915B-1D997676FEE2 Q35469598-118F19C0-62B3-479A-8256-77058313397A Q35540927-A0956181-E182-46DD-8312-20BEF746B5D3 Q35670887-1C0DB872-865E-4092-859E-3F1B19C7192A Q35792888-3279E971-99EC-47D4-8EF0-7597CE233FC5 Q35867011-3B20A6B1-E179-4785-9891-87DB70AD43CA Q36055389-9A3002AC-FAA7-448F-BA69-9F1416BEFB6F Q36112101-DBAC26C0-CDE9-4C95-B93B-26C72310F31C Q36371175-77470AAD-2686-46C0-9760-37993E84DFB9 Q36610373-0E0F0328-286A-447E-9A55-C690EF10DCE3 Q36869524-8C03B85C-CA02-4808-BD98-5F76724334F0 Q36887316-988CEDE0-E326-4381-BC10-A7375EA8159C Q37081950-5D329F7C-0632-4A21-8B71-F4801AEF0167 Q37119854-6C36D991-C14C-410A-AC55-A172EDAAFBF3 Q37281194-4062576C-CE9A-49EA-85CC-A664D2A59BA8 Q37352700-76AE5547-2619-4B48-B5C7-3564908E3909 Q37397820-9AA50289-EC9F-41C8-BB8C-C132CB2E2434 Q37399033-02715D58-8656-456E-AA1F-E086741E7F85 Q37403476-005F571E-A8C5-487A-99F1-396C0249910A Q37538771-D4B2A4C7-B95A-4B81-B0EC-9AF6DA6B1B0B Q37586538-3C7CD842-B111-4353-A36F-4C01FC8B0EA4 Q37596784-137D8969-EB55-4ECF-B0DF-B5A36055B933

P2860

Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis.

http://www.wikidata.org/entity/Q36494558

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Reversal of axonal loss and di ...... rogressive multiple sclerosis.

@ast

Reversal of axonal loss and di ...... rogressive multiple sclerosis.

@en

type

label

Reversal of axonal loss and di ...... rogressive multiple sclerosis.

@ast

Reversal of axonal loss and di ...... rogressive multiple sclerosis.

@en

prefLabel

Reversal of axonal loss and di ...... rogressive multiple sclerosis.

@ast

Reversal of axonal loss and di ...... rogressive multiple sclerosis.

@en

P1433

Q36494558-0DE09C96-FCAF-40B7-A71B-D8C3CEDD010E

P1476

Q36494558-95EDC243-28F5-406D-A86C-012D639F84F6

P2093

Q36494558-0FD0D05A-3592-461D-BA05-E51A35DF83D1

Q36494558-1076D22E-E45E-43D0-9E1D-117442F893B7

Q36494558-2D1F5509-7EE5-41E4-BAA4-870DFC059F21

Q36494558-3ADADF01-E994-4893-8421-15683DC244AE

Q36494558-6B71C694-98CC-4385-85A7-256301A3E8E3

Q36494558-7F5C7D35-AAC1-42FA-BB06-B1E2757638D7

Q36494558-8F04C316-424C-4C37-A1C4-5E69A1E45F9E

Q36494558-A6DFF0F9-37C0-461C-8E2F-1B769DD995E9

P2860

Q36494558-01A5D69F-5E67-4169-8ED1-20BD0361DB26

Q36494558-029EEEF0-FC2D-4616-B4F8-49F9E303B609

Q36494558-02F25054-8A93-4600-949F-9A2407B02169

Q36494558-04649E8F-2C97-44D6-AF27-3304772C4A71

Q36494558-13EA1D0F-4C2C-476E-A243-17253717B307

Q36494558-13F4CE77-A818-45A2-A8F2-37EA83C2B677

Q36494558-1A83E068-CFA6-4F9C-8BCB-58C3D3DDDFA4

Q36494558-20836645-407E-4214-9686-659080AFC587

Q36494558-244C7C8A-7886-43F1-A649-861EA381E010

Q36494558-2601F1CA-D956-4AD3-8DE5-9C195C10998D

P304

Q36494558-5A5698F4-6FF4-4CB3-AC88-156B1E3FD697

P31

Q36494558-82C9433F-D362-4970-879E-A6E7A81F33C4

P356

Q36494558-B4E475E4-8B14-4E66-92F3-ABC653609312

P407

Q36494558-2A200485-8C19-4974-9B78-96A8953580D6

P433

Q36494558-147BD48B-8F17-4B4F-8F2C-CBCDF12D6B31

P478

Q36494558-9BB69CBA-F42A-4A67-B2C9-036786D2958C

P50

Q36494558-0BE910F0-0908-46C8-8AF7-020791F9F94B

Q36494558-867E4C6B-F3E3-4761-8921-8D94462EEC89

Q36494558-C74F1A78-84F2-4C41-9B61-A9844F19C95F

P577

Q36494558-3E4443B2-2AAE-479E-BC81-810A586388C1

P5875

Q36494558-07BD11E6-CD0C-4BCB-B278-CF83A3EBB8DE

P698

Q36494558-13433DF6-422A-439C-97B4-4AB2B1C43803

P921

Q36494558-D74B0BE8-9350-4B3F-A359-08F4D913FC80

Q36494558-F22DE44C-6189-49FA-85AF-0031EE98F51C

P932

Q36494558-6A3A682D-DD36-4409-AA44-EF306F34881C

P356

P1433

Journal of Clinical Investigation

P1476

Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis

@en

P2093

Alexandre S Basso

http://www.w3.org/2001/XMLSchema#string

Alon Monsonego

http://www.w3.org/2001/XMLSchema#string

Amnon Bar-Shir

http://www.w3.org/2001/XMLSchema#string

Dan Frenkel

http://www.w3.org/2001/XMLSchema#string

Francisco J Quintana

http://www.w3.org/2001/XMLSchema#string

Lindsay Puckett

http://www.w3.org/2001/XMLSchema#string

Sanja Petrovic-Stojkovic

http://www.w3.org/2001/XMLSchema#string

Yoni Engel

http://www.w3.org/2001/XMLSchema#string

P2860

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

Excitatory amino acids and multiple sclerosis: evidence from cerebrospinal fluid

The chemical biology of clinically tolerated NMDA receptor antagonists

New targets for pharmacological intervention in the glutamatergic synapse

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis

Multiple sclerosis

Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data.

Selective targeting of an antioxidant to mitochondria.

Intercellular metabolic compartmentation in the brain: past, present and future.

P304

1532-1543

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI33464

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P50

Howard L. Weiner

Frederico Azevedo Costa-Pinto

P577

2008-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5512720

http://www.w3.org/2001/XMLSchema#string

P698

18340379

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis

P932

2267014

http://www.w3.org/2001/XMLSchema#string